Despite these challenges, our results underscore the dual molecular and functional benefits of ATM inhibition, positioning AZD1390 as a promising therapeutic candidate for mitigating the genotoxic stress, neuroinflammation, and motor deficits characteristic of PD. The gene discussed is ATM; the disease is Parkinson disease.